These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 31500657)

  • 1. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.
    Yu B; Liu D
    J Hematol Oncol; 2019 Sep; 12(1):94. PubMed ID: 31500657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.
    Robak T; Robak E
    Expert Opin Investig Drugs; 2014 Jul; 23(7):911-24. PubMed ID: 24708159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging antibody-drug conjugates for treating lymphoid malignancies.
    Wolska-Washer A; Robak P; Smolewski P; Robak T
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):259-273. PubMed ID: 28792782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
    Herrera AF; Molina A
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Antibody Drug Conjugates for Lymphoma.
    Russler-Germain DA; Kahl BS
    Oncology (Williston Park); 2020 Dec; 34(12):522-534. PubMed ID: 33395492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
    Chu Y; Zhou X; Wang X
    J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linked-in: design and efficacy of antibody drug conjugates in oncology.
    Feld J; Barta SK; Schinke C; Braunschweig I; Zhou Y; Verma AK
    Oncotarget; 2013 Mar; 4(3):397-412. PubMed ID: 23651630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving Landscape of Antibody Drug Conjugates in Lymphoma.
    Prakash R; Subbiah V; Iyer SP
    Cancer J; 2022 Nov-Dec 01; 28(6):479-487. PubMed ID: 36383911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.
    Burke JM; Morschhauser F; Andorsky D; Lee C; Sharman JP
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1073-1083. PubMed ID: 32985934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
    Mehta A; Forero-Torres A
    Curr Oncol Rep; 2015 Sep; 17(9):41. PubMed ID: 26194424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development].
    Ida N; Yamauchi T
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):686-690. PubMed ID: 39191681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugate technology development for hematologic disorders.
    Bander NH; Czuczman MS; Younes A
    Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates in hematologic malignancies.
    Leslie LA; Younes A
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.
    Ma H; Sawas A
    Curr Hematol Malig Rep; 2018 Dec; 13(6):555-569. PubMed ID: 30362019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.
    Beck A; Senter P; Chari R
    MAbs; 2011; 3(4):331-7. PubMed ID: 21691144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibody-drug conjugates: a new therapeutic class?].
    Chofflon I; Dietrich PY; Thang NN
    Rev Med Suisse; 2013 May; 9(387):1080-2, 1084-6. PubMed ID: 23757915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.